When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

Despite major advances in recent years, immunosuppressive regimens for multiple
sclerosis, rheumatoid arthritis, systemic lupus erythematosus and graft‐versus‐host disease …

The bone marrow (BM) microenvironment, also called the BM niche, is essential for the
maintenance of fully functional blood cell formation (hematopoiesis) throughout life. Under …

The coronavirus disease 2019 (COVID-19) pandemic, a viral illness caused by the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), 1 has produced at the time of this …

Conditioning-induced damage of the intestinal tract plays a critical role during the onset of
acute graft-versus-host disease (GVHD). Therapeutic interference with these early events of …

Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with
hematological malignancies. Endothelial dysfunction was linked to major complications after …

Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation
can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and …

Background Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory
graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. We aimed to …

The concept of allogeneic cell therapy was first presented over 60 years ago with
hematopoietic stem cell transplantation. However, complications such as graft versus host …

Clinical studies have suggested a potential involvement of endothelial dysfunction and
damage in the development and severity of acute graft-versus-host disease (aGvHD) …